– CANADA, Dieppe – Hexiris Inc., a leading R&D medtech company dedicated to developing innovative, accessible, and effective ophthalmic solutions for patients and community ophthalmologists, announced the appointments of Paul Sowyrda and Steven Schiffman to its Board of Directors.
About Paul Sowyrda
With over 25 years of experience in the life sciences industry, Paul Sowyrda has demonstrated leadership across every phase of development. He currently serves on the Board of Directors at Alloplex Biotherapeutics and the Society of Concurrent Product Development. As co-founder of Novellus, Inc., he played a key role in its evolution until its acquisition by Brooklyn ImmunoTherapeutics, Inc. in 2021. He has held leadership positions such as VP of Drug Development at CIBA and VP of Development and Marketing at Dusa Pharmaceuticals, which was later acquired by Sun Pharma. Currently, he is the VP of Business Development at Citius Pharmaceuticals and Citius Oncology. An accomplished inventor, he holds more than 15 patents and has consistently driven innovation throughout his career.
About Steven Schiffman
Steven Schiffman brings more than 35 years of executive experience across finance, private equity, and venture capital. He recently retired as CFO of Devonshire Investors, the private investment arm of Fidelity Investments, and as Interim President of Eight Roads Ventures, one of the world’s largest venture capital platforms. His leadership has spanned industries such as financial services, hospitality, consumer goods, transportation, and technology, where he managed multi-billion-dollar transactions and transformations. Mr. Schiffman has also served on numerous corporate boards.
About Hexiris
Hexiris is a leading medtech company committed to advancing ophthalmic devices that simplify treatments and improve access for worldwide patients in need. Our goal is to empower ophthalmologists with tools that are not only effective but also practical in diverse clinical settings.
Currently, Hexiris is developing several groundbreaking devices. One example is our Advanced Technology Device designed for office-based Minimally Invasive Glaucoma Surgeries. This first-of-its-kind innovation has been tested and holds the promise of transforming glaucoma care by making it simpler and more accessible for both patients and practitioners.
For more information: https://hexiris.ca/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.